The report by Human Rights Watch was released as the international community weighs how to respond to the attack on the Damascus suburb of Ghouta, which the US, France and others also have blamed on President Bashar Assad's forces. The regime blames the rebels.
President Barack Obama had been lobbying for targeted military strikes against regime positions, but a Russian proposal to put Assad's chemical weapons arsenal under international control has raised hopes of a diplomatic breakthrough instead.
Human Rights Watch did not have direct access to the affected areas or the victims, but said its conclusions are based on witness accounts, the physical fragments of the weapons used and the symptoms exhibited by victims and documented by medical staff.
The New York-based group said it sought technical advice from an expert on the detection and effects of chemical warfare agents, and its experts studied documented medical symptoms of the victims and analysed activist videos posted on the Internet after the attack.
Symptoms of the victims from the attack "provide telltale evidence about the weapon systems used," he added.
Three doctors who treated victims told HRW that the exhibited a range of symptoms, including convulsions, frothing at the mouth and dizziness, all of which are consistent with exposure to nerve agents such as sarin.
The most toxic of the chemical weapons, nerve agents affect the nervous system and are hazardous in their liquid and gas states. They can be delivered in missiles, bombs, rockets, artillery shells and other large munitions. The Syrian regime is believed to possess tabun, sarin and VX.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
